285 related articles for article (PubMed ID: 26222673)
21. Molecular Classification of Medullobastomas by Whole Genome Expression Profiling.
Nosková H; Adamcová S; Knoflíčková LDR; Pavelka Z; Vejmělková K; Zitterbart K; Slabý O; Štěrba J
Klin Onkol; 2019; 32(Supplementum1):171-173. PubMed ID: 31064192
[TBL] [Abstract][Full Text] [Related]
22. [Molecular subgrouping and characterization analysis of medulloblastomas in a cohort of Japanese patients].
Wataya T; Hamasaki M; Taylor MD
No Shinkei Geka; 2015 Feb; 43(2):117-25. PubMed ID: 25672552
[TBL] [Abstract][Full Text] [Related]
23. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
[TBL] [Abstract][Full Text] [Related]
24. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies.
Schwalbe EC; Williamson D; Lindsey JC; Hamilton D; Ryan SL; Megahed H; Garami M; Hauser P; Dembowska-Baginska B; Perek D; Northcott PA; Taylor MD; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2013 Mar; 125(3):359-71. PubMed ID: 23291781
[TBL] [Abstract][Full Text] [Related]
25. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
[TBL] [Abstract][Full Text] [Related]
26. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
[TBL] [Abstract][Full Text] [Related]
27. Implications of tumor location on subtypes of medulloblastoma.
Teo WY; Shen J; Su JM; Yu A; Wang J; Chow WY; Li X; Jones J; Dauser R; Whitehead W; Adesina AM; Chintagumpala M; Man TK; Lau CC
Pediatr Blood Cancer; 2013 Sep; 60(9):1408-10. PubMed ID: 23512859
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Clinical and Molecular Wnt and SHH Subgroups in Medulloblastoma Tumor Cases.
Kaya IS; Aksoy S; Mutlu M; Tekin C; Taskapilioglu MO; Tunca B; Civan MN; Ocak PE; Kocaeli H; Bekar A; Egeli U; Cecener G; Tolunay S
Turk Neurosurg; 2021; 31(4):554-565. PubMed ID: 33978203
[TBL] [Abstract][Full Text] [Related]
29. Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups.
Eid AM; Heabah NAE
J Egypt Natl Canc Inst; 2021 Feb; 33(1):6. PubMed ID: 33555447
[TBL] [Abstract][Full Text] [Related]
30. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
Ramaswamy V; Remke M; Bouffet E; Faria CC; Perreault S; Cho YJ; Shih DJ; Luu B; Dubuc AM; Northcott PA; Schüller U; Gururangan S; McLendon R; Bigner D; Fouladi M; Ligon KL; Pomeroy SL; Dunn S; Triscott J; Jabado N; Fontebasso A; Jones DT; Kool M; Karajannis MA; Gardner SL; Zagzag D; Nunes S; Pimentel J; Mora J; Lipp E; Walter AW; Ryzhova M; Zheludkova O; Kumirova E; Alshami J; Croul SE; Rutka JT; Hawkins C; Tabori U; Codispoti KE; Packer RJ; Pfister SM; Korshunov A; Taylor MD
Lancet Oncol; 2013 Nov; 14(12):1200-7. PubMed ID: 24140199
[TBL] [Abstract][Full Text] [Related]
31. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
[TBL] [Abstract][Full Text] [Related]
32. Advanced MRI Findings in Medulloblastomas: Relationship to Genetic Subtypes, Histopathology, and Immunohistochemistry.
Reis J; Stahl R; Zimmermann H; Ruf V; Thon N; Kunz M; Liebig T; Forbrig R
J Neuroimaging; 2021 Mar; 31(2):306-316. PubMed ID: 33465267
[TBL] [Abstract][Full Text] [Related]
33. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
[TBL] [Abstract][Full Text] [Related]
34. Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.
Cambruzzi E
Childs Nerv Syst; 2018 May; 34(5):809-815. PubMed ID: 29582169
[TBL] [Abstract][Full Text] [Related]
35. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
[TBL] [Abstract][Full Text] [Related]
36. Integration of immunohistochemistry, RNA sequencing, and multiplex ligation-dependent probe amplification for molecular classification of pediatric medulloblastoma.
Huang HY; Yu CH; Yang YL; Chang YH; Jou ST; Lin KH; Lu MY; Chang HH; Chou SW; Ni YL; Lin DT; Chen HY; Peng SS; Kuo MF; Yang SH
Pediatr Blood Cancer; 2022 Apr; 69(4):e29569. PubMed ID: 35119194
[TBL] [Abstract][Full Text] [Related]
37. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R
PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486
[TBL] [Abstract][Full Text] [Related]
38. Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy.
Blüml S; Margol AS; Sposto R; Kennedy RJ; Robison NJ; Vali M; Hung LT; Muthugounder S; Finlay JL; Erdreich-Epstein A; Gilles FH; Judkins AR; Krieger MD; Dhall G; Nelson MD; Asgharzadeh S
Neuro Oncol; 2016 Jan; 18(1):126-31. PubMed ID: 26254476
[TBL] [Abstract][Full Text] [Related]
39. Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice.
Gupta T; Shirsat N; Jalali R
Curr Pediatr Rev; 2015; 11(2):106-19. PubMed ID: 26133181
[TBL] [Abstract][Full Text] [Related]
40. Rapid diagnosis of medulloblastoma molecular subgroups.
Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
